Towards Healthcare
Bioconjugation Market Size Expands by 15.46% CAGR till 2034

Bioconjugation Market 2025 CRO/CDMO Segment to Outpace Industry with Rapid Expansion

According to market projections, the bioconjugation sector is expected to grow from USD 5.52 billion in 2024 to USD 23.18 billion by 2034, reflecting a CAGR of 15.46%. Bioconjugation is playing a vital role in next-generation diagnostic tools such as biosensors, imaging agents, and immunoassays. The demand for early and accurate disease detection is growing, especially in oncology and infectious diseases, thus boosting market potential.

  • Insight Code: 5974
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The Bioconjugation market is projected to reach USD 23.18 billion by 2034, growing at a CAGR of 15.46% from 2024 to 2034.

North America is currently leading the Bioconjugation market due to growing approval by the regulatory body, as well as rising prevalence of chronic diseases in the region.

The Bioconjugation market includes four segments including by product type, by application, by conjugation chemistry, by end user, and by region.

Some key players include Thermo Fisher Scientific, Inc., Merck KGaA, Creative Biolabs, Abcam plc, Sevion Therapeutics SciClone, Biomatik Corporation, and Agilent Technologies, Inc., among others.

Ministry of Health and Family Welfare, Association for Diagnostics & Laboratory Medicine (ADLM), American Clinical Laboratory Association, Government of India, National Institutes of Health, FDA, WHO, PIB, and CDC, among others.